KR870002158A - Hmg-coa 환원효소 억제제의 제조방법 - Google Patents

Hmg-coa 환원효소 억제제의 제조방법 Download PDF

Info

Publication number
KR870002158A
KR870002158A KR1019860006430A KR860006430A KR870002158A KR 870002158 A KR870002158 A KR 870002158A KR 1019860006430 A KR1019860006430 A KR 1019860006430A KR 860006430 A KR860006430 A KR 860006430A KR 870002158 A KR870002158 A KR 870002158A
Authority
KR
South Korea
Prior art keywords
dimethyl
compound
alkyl
hydrogen
formula
Prior art date
Application number
KR1019860006430A
Other languages
English (en)
Inventor
에프. 호프만 윌리엄
엘. 스미드 로버트
워드 스콜릭 에드
Original Assignee
제임스 에프. 노오턴
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 노오턴, 머크 앤드 캄파니 인코포레이티드 filed Critical 제임스 에프. 노오턴
Publication of KR870002158A publication Critical patent/KR870002158A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

HMG-COA 환원효소 억제제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. (a) 하기 일반식(4)의 화합물을 테트라(C1-5알킬)암모늄 할라이드 및 유기산으로 처리하여 R이(C1-5알킬)이고 R3가 수소인 일반식(II)의 화합물을 생성시키고: (b) 임의로, 단계(a)로부터 생성된 화합물을 산성 조건하에 처리하여 R 및 R3가 수소인 일반식(II)의 화합물을 생성시키고: (c) 임의로, 단계(a) 또는 단계(b)로부터 생성된 화합물을 처리함으로써 디하이드록시산을 재락톤화시켜 일반식(I)의 화합물을 생성시키고: (d) 임의로, 단계(a) 또는 단계(b)로부터 생성된 화합물을 C1-5알칸을 또는 치환된 C1-5알칸올로 처리하여 R3가 C1-5알킬이거나, 페닐, 디메틸아미노 또는 아세틸아미노 그룹으로 치환된 C1-5알킬인 일반식(II)의 화합물을 생성시킴을 특징으로 하여, 하기 일반식(I) 또는 (II)로 나타내어지는 화합물 또는 R3가 수소인 일반식(II)화합물의 약제학적으로 허용되는 염을 제조하는 방법.
    상기 식에서, m은 1 내지 5이고: R은 수소 또는 (C1-5알킬)이며: R1은 수소 또는 메틸이고: R2는 수소 또는 메틸이며: R3는 수소:C1-5알킬: 또는 페닐, 디메틸아미노 또는 아세틸아미노로 이루어진 그룹 중의 한 치환체로 치환된 C1-5알킬이고: R'는(C1-5알킬)이며: a, b 및 c에서 점선은 임의의 이중결합을 나타낸다.
  2. 제1항에 있어서, n이 1내지 3이고 R2가 메틸인 방법.
  3. 제2항에 있어서, a,b또는 c에서의 점선중 하나가 이중 결합을 나타내거나 a 및 c에서의 점선이 이중결합을 나타내는 방법.
  4. 제3항에 있어서, a 및 c에서의 점선이 이중결합을 나타내는 방법.
  5. 제4항에 있어서, 제조된 화합물이 6(R)-[2-[8(S)-(2-메틸-4'-하이드록시부티릴옥시)-2(S),6(R)-디메틸-1,2,6,7,8,8a(R)-헥사하이드로나프틸-1(S)]에틸]-4(R)-하이드록시-3,4,5,6-테트라하이드로-2H-피란-2-온 또는 7-[1,2,6,7,8,8a(R)-헥사하이드로-2(S),6(R)-디메틸-8(S)-(2-메틸-4-하이드록시부티릴옥시)나프탈레닐-1(S)]-3(R),5(R)-디하이드록시헵타노산인 방법.
  6. 제4항에 있어서, R1이 메틸인 방법.
  7. 제6항에 있어서, 제조된 화합물이 6(R)-[2-8(S)-(2,2-디메틸-4-하이드록시부티릴옥시)-2(S),6(R)-디메틸-1,2,6,7,8,8a(R)-헥사하이드로나프틸-1(S)]에틸]-4(R)-하이드록시-3,4,5,6-테트라하이드로-2H-피란-2-온 및 7-[1,2,6,7,8,8a(R)-헥사하이드로-2(S), 6(R)-디메틸-8(S)-(2,2-디메틸-4-하이드록시부티릴옥시)나프탈레닐-1(S)]-3(R),5(R)-디하이드록시헵타노산: 6(R)-[2-[8(S)-(2,2-디메틸-5-하이드록시펜타노일옥시)-2(S),6(R)-디메틸-1,2,6,7,8,8a(R)-헥사하이드로나프틸-1(S)]에틸]-4(R)-하이드록시-3,4,5,6-테트라하이드로-2H-피란-2-온 및 7-[1,2,6,7,8,8a(R)-헥사하이드로-2(S),6(R)-디메틸-8(S)-(2,2-디메틸-5-하이드록시펜타노일옥시)나프탈레닐-1(S)]-3(R),5(R)-디하이드록시헵타노산 : 또는 6(R)-[2-[(S)-(2,2-디메틸-3-하이드록시프로피오닐옥시)-2(S),6(R)-디메틸-1,2,6,7,8,8a(R)-헥사하이드로나프틸-1(S)]에틸]-4(R)-하이드록시-3,4,5,6-테트라하이드로-2H-피란-2-온 및 7-[1,2,6,7,8,8a(R)-헥사하이드로-2(S),6(R)-디메틸-8(S)-(2,2-디메틸-3-하이드록시피오닐옥시)나프탈레닐-1(S)]-3(R),5(R)-디하이드록시헵타노산인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860006430A 1985-08-05 1986-08-04 Hmg-coa 환원효소 억제제의 제조방법 KR870002158A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/762,736 US4668699A (en) 1985-08-05 1985-08-05 Novel HMG-CoA reductase inhibitors
US762736 1996-12-10

Publications (1)

Publication Number Publication Date
KR870002158A true KR870002158A (ko) 1987-03-30

Family

ID=25065902

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860006430A KR870002158A (ko) 1985-08-05 1986-08-04 Hmg-coa 환원효소 억제제의 제조방법

Country Status (13)

Country Link
US (2) US4668699A (ko)
EP (1) EP0211416B1 (ko)
JP (1) JPS6233133A (ko)
KR (1) KR870002158A (ko)
AU (1) AU6084686A (ko)
CA (1) CA1291143C (ko)
DE (1) DE3681991D1 (ko)
DK (1) DK370486A (ko)
ES (1) ES2000842A6 (ko)
GR (1) GR862006B (ko)
IL (1) IL79530A0 (ko)
PT (1) PT83077B (ko)
ZA (1) ZA865779B (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4916162A (en) * 1986-05-05 1990-04-10 Merck & Co., Inc. Antihypercholesterolemic compounds
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4789682A (en) * 1987-03-17 1988-12-06 Merck & Co., Inc. Antihypercholesterolemic compounds
US4845237A (en) * 1987-04-15 1989-07-04 Merck & Co., Inc. Acylation process for the synthesis of HMG-CoA reductase inhibitors
PT88364A (pt) * 1987-09-02 1989-07-31 Merck & Co Inc Process for preparing novel hmg-coa reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4994494A (en) * 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4892884A (en) * 1987-12-21 1990-01-09 Rorer Pharmaceutical Corporation Novel hmg-coa reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4904692A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4866068A (en) * 1988-02-01 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
FI893004A (fi) * 1988-06-29 1989-12-30 Merck & Co Inc 5-oxygenerade hmg-coa-reduktas -inhibitorer.
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
US5073568A (en) * 1988-11-14 1991-12-17 Hoffmann-La Roche Inc. Antipsoriatic agents
US5200549A (en) * 1988-11-14 1993-04-06 Hoffman-La Roche Inc. Antipsoriatic agents
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5130306A (en) * 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) * 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
IL90847A0 (en) * 1989-06-09 1990-02-09 Merck & Co Inc 3-keto hmg-coa reductase inhibitors and pharmaceutical compositions containing them
GB8915280D0 (en) * 1989-07-04 1989-08-23 British Bio Technology Compounds
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4992429A (en) * 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
EP0415188B1 (en) * 1989-08-28 1996-03-20 F. Hoffmann-La Roche Ag Enzymatic method for determining analyte concentrations
US4946860A (en) * 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
US6630502B2 (en) 1990-05-15 2003-10-07 E.R. Squibb & Sons, Inc. Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
JP2003012607A (ja) * 2001-06-26 2003-01-15 Mercian Corp 新規なメバスタチン誘導体
AU2002366444A1 (en) * 2001-11-08 2003-09-09 Merck & Co., Inc. Compounds useful in the treatment of anthrax
KR20060013632A (ko) 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
US20040119052A1 (en) * 2002-12-20 2004-06-24 Beavers William Anthony Process for preparing alpha- and beta- methyl-gamma-butyrolactone and 3-methyltetrahydrofuran
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
CN104350036B (zh) * 2012-06-05 2017-05-17 帝斯曼知识产权资产管理有限公司 4‑烷酰氧基‑2‑甲基丁酸的生产方法
DK3638044T3 (da) * 2017-06-15 2024-06-10 Dsm Ip Assets Bv Frosne enzympellets
KR20200066690A (ko) 2017-10-16 2020-06-10 칭화대학교 메발로네이트 경로 억제제 및 이의 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4376863A (en) * 1981-08-21 1983-03-15 Merck & Co., Inc. Hypocholesterolemic fermentation products
JPS5835144A (ja) * 1981-08-27 1983-03-01 Sankyo Co Ltd Ｍｂ−５３０ｂ誘導体およびその製造法
EP0094443A1 (en) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same
JPS59122483A (ja) * 1982-12-28 1984-07-14 Nippon Chemiphar Co Ltd 新規なモナコリン誘導体
EP0137445B1 (en) * 1983-10-11 1990-01-03 Merck & Co. Inc. Process for c-methylation of 2-methylbutyrates
JPH09122483A (ja) * 1995-10-31 1997-05-13 Matsushita Electric Ind Co Ltd 窒素酸化物・硫黄酸化物吸収剤

Also Published As

Publication number Publication date
IL79530A0 (en) 1986-11-30
EP0211416A2 (en) 1987-02-25
ZA865779B (en) 1987-03-25
JPS6233133A (ja) 1987-02-13
PT83077B (en) 1988-07-13
DK370486D0 (da) 1986-08-04
EP0211416A3 (en) 1987-09-23
DK370486A (da) 1987-02-06
DE3681991D1 (de) 1991-11-21
EP0211416B1 (en) 1991-10-16
US4851436A (en) 1989-07-25
AU6084686A (en) 1987-02-12
CA1291143C (en) 1991-10-22
ES2000842A6 (es) 1988-03-16
PT83077A (en) 1986-08-01
GR862006B (en) 1986-12-23
US4668699A (en) 1987-05-26

Similar Documents

Publication Publication Date Title
KR870002158A (ko) Hmg-coa 환원효소 억제제의 제조방법
KR950002755A (ko) 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제
KR880000586A (ko) HMG-CoA 환원효소 억제제 및 이의 제조방법
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
KR880003893A (ko) 에티닐페닐을 함유하고 있는 레티오익산 유도체들
KR890002119A (ko) 3-데메틸메발론산 유도체, 이의 제조방법, 이 화합물을 기본으로 하는 약제학적 조성물, 이의 용도 및 중간체
KR850000426A (ko) 디하이드로 벤조피란 유도체의 제조방법
KR850000406A (ko) 4-클로로-2-페닐이미다졸-5-아세트산유도체의 제조방법
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
KR840004428A (ko) 벤조 아자시클로 알킬-스피로-이미다졸리딘의 제조방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
CA2053000A1 (en) Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula
KR890005080A (ko) HMG-CoA환원효소 억제제
KR850004754A (ko) 3-인돌 카르복사미드 화합물류의 제조방법
KR830007626A (ko) 2-(1,4-벤조디옥산-2-일알킬) 이미다졸류의 제조방법
KR960704840A (ko) 사이클로헥산디우레아 유도체 및 그의 제조방법 (cyclohexanediuea derivative and process for producing the same)
KR880005145A (ko) N-글리코릴네우라민산 함유 당지질 및 그 제조방법
KR830005263A (ko) 17α-아실록시-5β-코르티코이드 및 17α-아실록시-5α-코르티코이드의 제조방법
KR900011709A (ko) 신규한 테트랄린 유도체
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR830001900A (ko) 페닐모르판과 그의 중간물질및 제조방법
KR910006280A (ko) 이미다졸 유도체, 제약학적으로 허용가능한 이들의 산 부가염 및 이들의 제조 방법
EP0245004A3 (en) Antihypercholesterolemic compounds
GB1363814A (en) Cycloaliphatic compounds as odour and tastemodifying agents

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application